143 related articles for article (PubMed ID: 15139755)
1. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease.
Pierce AC; Rao G; Bemis GW
J Med Chem; 2004 May; 47(11):2768-75. PubMed ID: 15139755
[TBL] [Abstract][Full Text] [Related]
2. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
Liu Q; Masek B; Smith K; Smith J
J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
[TBL] [Abstract][Full Text] [Related]
3. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
Perola E; Walters WP; Charifson PS
Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
[TBL] [Abstract][Full Text] [Related]
4. E-novo: an automated workflow for efficient structure-based lead optimization.
Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
[TBL] [Abstract][Full Text] [Related]
5. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
6. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
7. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring.
Zhang Q; Muegge I
J Med Chem; 2006 Mar; 49(5):1536-48. PubMed ID: 16509572
[TBL] [Abstract][Full Text] [Related]
8. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
Meagher KL; Carlson HA
J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
[TBL] [Abstract][Full Text] [Related]
9. CONCERTS: dynamic connection of fragments as an approach to de novo ligand design.
Pearlman DA; Murcko MA
J Med Chem; 1996 Apr; 39(8):1651-63. PubMed ID: 8648605
[TBL] [Abstract][Full Text] [Related]
10. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.
Tominaga Y; Jorgensen WL
J Med Chem; 2004 May; 47(10):2534-49. PubMed ID: 15115396
[TBL] [Abstract][Full Text] [Related]
11. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
12. Ligand design package (Ludi--MSI) applied to known inhibitors of the HIV-1 protease. Test of performance.
Bogacewicz R; Trylska J; Geller M
Acta Pol Pharm; 2000 Nov; 57 Suppl():25-8. PubMed ID: 11293255
[TBL] [Abstract][Full Text] [Related]
13. Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.
Sadiq SK; Wright D; Watson SJ; Zasada SJ; Stoica I; Coveney PV
J Chem Inf Model; 2008 Sep; 48(9):1909-19. PubMed ID: 18710212
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
15. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.
Chang MW; Lindstrom W; Olson AJ; Belew RK
J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753
[TBL] [Abstract][Full Text] [Related]
17. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
Pillai B; Kannan KK; Bhat SV; Hosur MV
Acta Crystallogr D Biol Crystallogr; 2004 Mar; 60(Pt 3):594-6. PubMed ID: 14993705
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
19. CORES: an automated method for generating three-dimensional models of protein/ligand complexes.
Hare BJ; Walters WP; Caron PR; Bemis GW
J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488
[TBL] [Abstract][Full Text] [Related]
20. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
Li D; Liu MS; Ji B; Hwang K; Huang Y
J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
